N-Acetylcysteine prevents doxorubucine-induced cardiotoxicity in rats

Human and Experimental Toxicology

Volumn 32, Issue 6, 2013, Pages 655-661

  Arica, V ^a   Demir, I H ^b   Tutanc, M ^a   Basarslan, F ^a   Arica, S ^a   Karcioglu, M ^a   Ozturk H ^a   Nacar, A ^a  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b Hatay State Hospital   (Turkey)

Author keywords

cardiac toxicity; Doxorubucine; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; DOXORUBICIN; LACTATE DEHYDROGENASE; NITRIC OXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; CARDIOTOXICITY; CONTROLLED STUDY; EDEMA; ENZYME ACTIVITY; HEART MUSCLE; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SINGLE DRUG DOSE;

CARDIAC TOXICITY; DOXORUBUCINE; N-ACETYLCYSTEINE;

ACETYLCYSTEINE; ANIMALS; CARDIOMYOPATHIES; DOXORUBICIN; FREE RADICAL SCAVENGERS; NITRIC OXIDE; RATS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TOPOISOMERASE II INHIBITORS;

RATTUS;

EID: 84878308423     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327112467043     Document Type: Article

References (27)

1. Sahna E, Parlakpinar H, Ozer MK, et al. Melatonin protects against myocardial doxorubicin toxicity in rats: role of physiological concentrations. J Pineal Res. 2003 ; 35: 257-261
2. Hrelia S, Fiorentini D, Maraldi T, et al. Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes. Biochim Biophys Acta. 2002 ; 1567: 150-156
3. Cassidy SC, Chan DP, Rowland DG, et al. Effects of doxorubicin on diastolic function, contractile reserve, and ventricular-vascular coupling in piglets. Pediatr Cardiol. 1998 ; 19: 450-457
4. Saeki K, Obi I, Ogiku N, et al. Doxorubicin directly binds to the cardiac-type ryanodine receptor. Life Sci. 1998 ; 19: 450-457
5. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity analysis of prevailing hypotheses. FASEB J. 1990 ; 4: 3076-3086
6. Akimoto H, Bruno NA, Slate DL, et al. Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes. Cancer Res. 1993 ; 53: 4658-4664
7. Singal PK, Iliskovic N, Li T, et al. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 1997 ; 11: 931-936
8. Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 1987 ; 19: 817-828
9. Arakawa M, Ito Y. N-acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology. Cerebellum. 2007 ; 19: 1-7
10. Nitescu N, Ricksten SE, Marcussen N, et al. N-acetylcysteine attenuates kidney injury in rats subjected to renal ischaemia-reperfusion. Nephrol Dial Transplant. 2006 ; 21: 1240-1247
11. Fadillioǧlu E, Erdoǧan H. Effects of erdosteine treatment against doxorubicin-induced toxicity through erythrocyte and plasma oxidant/antioxidant status in rats. Pharmacol Res. 2003 ; 47: 317-322
12. Cortas NK, Wakid NW. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem. 1990 ; 36: 1440-1443
13. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem. 1988 ; 34: 497-500
14. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Meth Enzymol. 1990 ; 186: 407-421
15. Cigremis Y, ParlakpInar H, Polat A, et al. Beneficial role of aminoguanidine on acute cardiomyopathy related to doxorubucine treatment. Mol Cell Biochem. 2006 ; 85: 149-154
16. Wahab MH, Akoul ES, Abdel-Aziz AA. Modulatory effects of melatonin and vitamin E on doxorubicin-induced cardiotoxicity in Ehrlich ascites carcinoma-bearing mice. Tumori. 2000 ; 86: 157-162
17. Wozniak G, Anuszewska EL. Influence of vitamins C and E on cytotoxic activity of adriamycin in chosen cell cultures. Acta Pol Pharm. 2002 ; 59: 31-35
18. Boucher F, Coudray C, Tirard V, et al. Oral selenium supplementation in rats reduces cardiac toxicity of adriamycin during ischemia and reperfusion. Nutrition. 1995 ; 11: 708-711
19. Fadillioglu E, Erdogan H, Sogut S, et al. Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats. J Appl Toxicol. 2003 ; 23: 71-74
20. Santos DL, Moreno AJ, Leino RL, et al. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol. 2002 ; 185: 218-227
21. Herman EH, Ferrans VJ, Myers CE, et al. Comparison of the effectiveness of (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res. 1985 ; 45: 276-281
22. Kaya H, Koc A, Sogut S, et al. The protective effect of N-acetylcysteine against cyclosporine A-induced hepatotoxicity in rats. J Appl Toxicol. 2008 ; 28: 15-20
23. Sehirli AO, Sener G, Satiroglu H, et al. Protective effect of N-acetylcysteine on renal ischemia/reperfusion injury in the rat. J Nephrol. 2003 ; 16: 75-80
24. Yagmurca M, FadIllIoglu E, Erdogan H, et al. Erdosteine prevents doxorubicin-induced cardiotoxicity in rats. Pharmacol Res. 2003 ; 48: 377-382
25. Simůnek T, Stérba M, Popelová O, et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009 ; 61: 154-171
26. Khan M, Shobha JC, Mohan IK, et al. Protective effect of spirulina against doxorubicin-induced cardiotoxicity. Phytother Res. 2005 ; 19: 1030-1037
27. Saad SY, Najjar TA, Al-Rikabi AC. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res. 2001 ; 43: 211-218